Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer

Summary

This is an open-label, single-arm, multicenter study of capecitabine and bevacizumab administered as first-line treatment of previously untreated elderly patients, older than 70 years, with metastatic or locally recurrent breast cancer.

Timeline

Start

2010-05

Primary completion

2011-08

Completion

—

Drugs

Indications